Cadila Healthcare on Friday said that the USFDA inspected the company’s formulations manufacturing facility located at Moraiya, Ahmedabad, from April 22 to May 3. The inspection concluded with 14 observations. There were no repeat observations or Data Integrity-related observations, the company said, and added that it is confident of addressing these observations and responding to the USFDA at the earliest. Shareholders will closely monitor the developments.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.